Levemir® FlexTouch® FAQ

Learn about the key features, specifications, and use of Levemir® FlexTouch®.

Patient Brochure

Download information to help your patients understand the benefits of Levemir® and Levemir® FlexTouch®.

Free Samples

Get complimentary prescription drug samples of Levemir® and Levemir® FlexTouch®.


Formulary coverage

Levemir® is now exclusive Tier 1a on UnitedHealthcare® and preferred on Coventry. Available on more than 96% of Commerical and Medicare Part D plans nationwide.

 

aAverage Tier 1 co-pay may vary by benefit design. Does not include UnitedHealthcare Community Plan.

Levemir® FlexTouch® insulin pen audible dose delivery

End-of-Dose Clickb

FlexTouch® makes an audible end-of-dose clickb (dial resets to 0). 

bPatient may or may not hear an audible click at end of dose. Dose is delivered when dial resets to 0 and the needle is held in the skin for 6 seconds. If the needle is removed earlier, patients may see a stream of insulin coming from the needle. If so, this may result in a possible under-dose as much as 20%, and patient should be instructed to increase the frequency of checking their blood glucose levels with possible additional insulin administration. Please see Instructions For Use for complete instructions. 

Levemir® FlexTouch® insulin pen without an extending push button

No Push-Button Extension

FlexTouch® is the only prefilled insulin pen without an extending push button. No matter what dose is dialed, the FlexTouch® push button doesn't extend any higher. 

Up to 42 Days Unrefrigerated

Levemir® FlexTouch® lasts up to 42 days unrefrigerated.4,c

cMust be kept at room temperature, below 86°F (30°C) once in use. Levemir® FlexTouch® (opened or unopened) must be discarded 42 days after it is taken out of the refrigerator. 

“Regardless of dose size, Levemir® FlexTouch® enables patients to deliver insulin without having to reach for an extended push button. This new technology has the potential to make a difference in insulin administration for many of my patients.”

–Wendy S. Lane, MD

“No matter how much Levemir® I’m taking, it’s no longer a struggle to reach the push button with the Levemir®  FlexTouch®.  Would I recommend the Levemir® FlexTouch® to another patient? Definitely YES.”

–Martin L., Patient



NovoFine® needles: Designed with patients in mind

 

  • Single-use, disposable injection needles – available in 30G (8 mm) or 32G (6 mm)d
  • SuperFlow Technology™ designed to enhance flow rate and reduce dosing force when injecting
  • NovoFine® needles fit all major insulin devices
  • Little or no pain- A majority of patients using the NovoFine® 32G Tip needle experience little or no pain.5

 

dNeedles are sold separately and may require a prescription in some states. 

NovoFine® single­‐use, disposable insulin injection needles

Levemir® FlexPen® prefilled insulin pen

Levemir ® FlexPen ® Discontinuation

  • As a result of the launch of Levemir® FlexTouch®, Novo Nordisk will be discontinuing Levemir® FlexPen® on September 30, 2014. Levemir® FlexPen® will remain available in pharmacies while supplies last. Once their inventory is exhausted, no additional product will be available.  Therefore we encourage you to speak with your patients about Levemir® FlexTouch®.
  • A new prescription is required to convert patients from Levemir® FlexPen® to Levemir® FlexTouch®.
  • Levemir® FlexTouch® is offered to patients at no additional cost and will have the same coverage and co-pay as Levemir® FlexPen®. All patient savings plans for Levemir® will continue to be honored.


 

Related Prescribing Topics:

Selected Important Safety Information

Contraindications

  • Levemir® is contraindicated in patients with hypersensitivity to Levemir® or any of its excipients.

Warnings and Precautions

  • Dosage adjustment and monitoring: Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment of concomitant anti-diabetic treatment.
  • Administration: Do not dilute or mix with any other insulin or solution. Do not administer subcutaneously via an insulin pump, intramuscularly, or intravenously because severe hypoglycemia can occur. Needles, insulin pens, or syringes should never be shared.

Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

  • Levemir® (insulin detemir [rDNA origin] injection) is indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Limitations of Use

  • Levemir® is not recommended for the treatment of diabetic ketoacidosis. Intravenous rapid-acting or short-acting insulin is the preferred treatment for this condition.

Important Safety Information

Contraindications

  • Levemir® is contraindicated in patients with hypersensitivity to Levemir® or any of its excipients.

Warnings and Precautions

  • Dosage adjustment and monitoring: Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in the insulin dose or an adjustment of concomitant anti-diabetic treatment.

  • Administration: Do not dilute or mix with any other insulin or solution. Do not administer subcutaneously via an insulin pump, intramuscularly, or intravenously because severe hypoglycemia can occur. Needles, insulin pens, or syringes should never be shared.

  • Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin therapy and may be life-threatening. When a GLP-1 receptor agonist is used in combination with Levemir®, the Levemir® dose may need to be lowered or more conservatively titrated to minimize the risk of hypoglycemia.

  • Hypersensitivity and allergic reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Levemir®.

  • Renal and hepatic Impairment: Careful glucose monitoring and dose adjustments of insulin, including Levemir®, may be necessary in patients with renal or hepatic impairment.
  • Drug Interactions: Some medications may alter insulin requirements and subsequently increase the risk for hypoglycemia or hyperglycemia.
  • Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Levemir®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.

Adverse Reactions

  • Adverse reactions associated with Levemir® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, rash, pruritus, and if taken with GLP-1 receptor agonist, diarrhea.

Use in Specific Populations

  • Levemir® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.

  • The background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia.

Whether these observed weight results represent true effects of Levemir® and other therapies are not known since the trial was not blinded, and the protocol (eg, diet and exercise instructions and monitoring) was not specifically directed at exploring hypotheses related to weight effects of the treatments evaluated. The clinical significance of these observed effects has not been established.

Please click here for Prescribing Information.

 

References

  1. Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. FlexTouch: a prefilled insulin pen with novel injection mechanism with consistent high accuracy at low- (1 U), Medium- (40 U), and high- (80 U) dose settings. J Diabetes Sci Technol. 2011;5(5):1195-1199.
  2. Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen. Expert Opin. Drug Deliv. 2011;8(10):1271-1276.
  3. Hemmingsen H, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. A prefilled insulin pen with a novel injection mechanism and lower injection force than other prefilled insulin pens. Diabetes Technol Ther. 2011;13(12):1-5.
  4. Levemir [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2013. 
  5. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perception of pain, handling, and acceptability: A randomized, open-label, crossover study in subjects with diabetes. Diabetes Tech. 2009;11(3)195-201.